Phase 1/2 Open-Label Trial to Assess the Safety and Preliminary Efficacy of 177Lu-OPS201 as Peptide Receptor Radionuclide Therapy in Patients With Somatostatin Receptor-Positive, Progressive Neuroendocrine Tumors

被引：0
|
作者：
Nicolas, Guillaume [1 ,2 ]
Bodei, Lisa [3 ]
Baum, Richard [4 ]
Herrmann, Ken [5 ]
Lassmann, Michael [6 ]
Hicks, Rodney [7 ]
Navalkissoor, Shaunak [2 ]
Haug, Alexander [8 ]
Oberwittler, Heike [9 ]
Wang, Tiffany [10 ]
Wild, Damian [1 ]
机构：
[1] Univ Basel Hosp, Basel, Switzerland
[2] Royal Free Hosp, London, England
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Zent Klin Bad Berka, Bad Berka, Germany
[5] Univ Calif Los Angeles, Los Angeles, CA USA
[6] Univ Hosp Wurzburg, Wurzburg, Germany
[7] Peter MacCallum Canc Ctr, East Melbourne, Australia
[8] Med Univ Vienna, Vienna, Austria
[9] Ipsen, Les Ulis, France
[10] Ipsen, Cambridge, MA USA
来源：
PANCREAS | 2018年 / 47卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：349 / 349
页数：1
相关论文
共 50 条
  • [21] Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177Lu-Dotatate (Lutathera) (LU) in neuroendocrine tumors (NETs)
    Navarro Martin, M.
    Teran Brage, E.
    Campana-Diaz, E.
    Garcia-Talavera, P.
    Reguera Puertas, P.
    Rama-Alonso, S.
    Garijo-Martinez, M. C.
    Felix, L. C.
    Diaz Sanchez, P.
    Vidal Tocino, R.
    Fonseca Sanchez, E.
    ANNALS OF ONCOLOGY, 2024, 35 : S95 - S95
  • [22] Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting
    Kalshetty, Ashwini
    Ramaswamy, Anant
    Ostwal, Vikas
    Basu, Sandip
    NUCLEAR MEDICINE COMMUNICATIONS, 2018, 39 (12) : 1143 - 1149
  • [23] Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: preliminary dosimetry, efficacy and safety results from the P-PRRT trial
    Del Prete, M.
    Arsenault, F.
    Saighi, N.
    Bouchard, L. O.
    Beaulieu, A.
    Buteau, F. A.
    Beauregard, J. M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S60 - S61
  • [24] Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumors: initial dosimetry and safety results of the P-PRRT trial
    Del Prete, Michela
    Buteau, Francois-Alexandre
    Beaulieu, Alexis
    Beauregard, Jean-Mathieu
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [25] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
    Swiha, Mina M.
    Sutherland, Duncan E. K.
    Sistani, Golmehr
    Khatami, Alireza
    Abazid, Rami M.
    Mujoomdar, Amol
    Wiseman, Daniele P.
    Romsa, Jonathan G.
    Reid, Robert H.
    Laidley, David T.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (01) : 225 - 236
  • [26] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
    Mina M. Swiha
    Duncan E. K. Sutherland
    Golmehr Sistani
    Alireza Khatami
    Rami M. Abazid
    Amol Mujoomdar
    Daniele P. Wiseman
    Jonathan G. Romsa
    Robert H. Reid
    David T. Laidley
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 225 - 236
  • [27] Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma
    Minczeles, Noemie S.
    Bos, Eelke M. M.
    de Leeuw, Reinoud C. C.
    Kros, Johan M. M.
    Konijnenberg, Mark W. W.
    Bromberg, Jacoline E. C.
    de Herder, Wouter W. W.
    Dirven, Clemens M. F.
    Hofland, Johannes
    Brabander, Tessa
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (04) : 1195 - 1204
  • [28] Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma
    Noémie S. Minczeles
    Eelke M. Bos
    Reinoud C. de Leeuw
    Johan M. Kros
    Mark W. Konijnenberg
    Jacoline E. C. Bromberg
    Wouter W. de Herder
    Clemens M. F. Dirven
    Johannes Hofland
    Tessa Brabander
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 1195 - 1204
  • [29] Safety and efficacy of 177Lu DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) in progressive gastro-entero-pancreatic (GEP) Neuroendocrine Tumour (NET)
    Alipour, R.
    Karri, R. K.
    Boehm, E.
    Jewell, K.
    Fahey, M.
    Saghebi, J.
    Cardin, A.
    Neeson, L.
    Buteau, J. P.
    Kumar, A. Ravi
    Akhurst, T.
    Hofman, M.
    Michael, M.
    Hicks, R.
    Kong, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S665 - S666
  • [30] A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Chauhan, A.
    Kunos, C.
    El Khouli, R.
    Kolesar, J.
    Evers, B. M.
    Kidd, M.
    Kohn, E.
    Anthony, L.
    PANCREAS, 2021, 50 (03) : 467 - 467
12345